Alx Oncology Holdings (ALXO) Times Interest Earned (2019 - 2026)
Alx Oncology Holdings recorded quarterly Times Interest Earned of -$57.3 in Q1 2026, up 4.67% quarter-over-quarter from -$60.11 in Q4 2025, and up 26.89% year-over-year from -$45.16 in Q1 2025.
Alx Oncology Holdings' Times Interest Earned history runs 7 years deep, the most recent figure standing at -$57.3 for Q1 2026.
- In Q1 2026, Times Interest Earned rose 26.89% year-over-year to -$57.3; the TTM figure through Mar 2026 stood at -$59.7 (up 25.31% YoY), while the FY2025 annual figure was -$64.93, up 21.2% from the prior year.
- Times Interest Earned came in at -$57.3 for Q1 2026 at Alx Oncology Holdings, up from -$60.11 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $213.22 in Q4 2023 to a low of -$18340.5 in Q3 2022.
- A 5-year average of -$2610.3 and a median of -$83.21 in 2023 frame the typical range for Times Interest Earned.
- Across the five-year window, Times Interest Earned jumped 252.87% in 2023 and plunged 133.62% in 2024, its largest moves.
- Alx Oncology Holdings' Times Interest Earned stood at -$139.48 in 2022, then surged by 252.87% to $213.22 in 2023, then slumped by 133.62% to -$71.69 in 2024, then gained by 16.16% to -$60.11 in 2025, then gained by 4.67% to -$57.3 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$57.3, -$60.11, and -$55.23 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - | -57.30 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -57.30 |
| Dec 31, 2025 | -60.11 |
| Sep 30, 2025 | -55.23 |
| Jun 30, 2025 | -65.80 |
| Mar 31, 2025 | -78.37 |
| Dec 31, 2024 | -71.69 |
| Sep 30, 2024 | -73.02 |
| Jun 30, 2024 | -96.79 |
| Mar 31, 2024 | -88.44 |
| Dec 31, 2023 | 213.22 |
| Sep 30, 2023 | -136.25 |
| Jun 30, 2023 | -98.86 |
| Mar 31, 2023 | -83.21 |
| Dec 31, 2022 | -139.48 |
| Sep 30, 2022 | -18,340.50 |
| Jun 30, 2022 | -16,894.50 |
| Mar 31, 2022 | -8,249.00 |
| Dec 31, 2020 | -3,256.60 |
| Sep 30, 2020 | -88.37 |
| Jun 30, 2020 | -35.37 |
| Dec 31, 2019 | -7,733.00 |
| Sep 30, 2019 | -1,517.00 |